![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00558272 |
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
Condition | Intervention | Phase |
Breast Cancer Prostate Cancer Bone Neoplasms |
Drug: AZD0530 Drug: Zoledronic Acid Drug: Calcium Drug: Vitamin D |
Phase II |
Genetics Home Reference related topics: | breast cancer |
MedlinePlus related topics: | Bone Cancer Bone Diseases Breast Cancer Cancer Prostate Cancer |
ChemIDplus related topics: | Zoledronic acid Calcium gluconate Vitamin D Ergocalciferol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease. |
Estimated Enrollment: | 122 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: AZD0530 Clinical Trials Mailbox | AZD0530ClinicalTrialsMailbox@astrazeneca.com |
![]() |
Show 25 Study Locations |
AstraZeneca |
Study Director: | Richard Finkelman, DDS, PhD | AstraZeneca |
Principal Investigator: | Meabe Aklilu, MD | Wake Forest University |
Responsible Party: | AstraZeneca Pharmaceuticals ( Mary Stuart, MD - Medical Science Director EPT1 ) |
Study ID Numbers: | D8180C00034 |
First Received: | November 13, 2007 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00558272 |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada; Denmark: Danish Medicines Agency; Spain: Spanish Agency of Medicines; Sweden: Medical Products Agency; Norway: Norwegian Medicines Agency; Portugal: National Pharmacy and Medicines Institute; United Kingdom: Medicines and Healthcare Products Regulatory Agency |
|
|
|
|
![]() |